Divergent Planning LLC Invests $45,000 in Health Catalyst, Inc. $HCAT

Divergent Planning LLC purchased a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 10,998 shares of the company’s stock, valued at approximately $45,000.

Several other institutional investors and hedge funds have also bought and sold shares of HCAT. Inspire Investing LLC grew its holdings in shares of Health Catalyst by 36.3% during the 2nd quarter. Inspire Investing LLC now owns 103,494 shares of the company’s stock worth $390,000 after acquiring an additional 27,582 shares during the period. HighMark Wealth Management LLC raised its holdings in Health Catalyst by 13,080.0% in the second quarter. HighMark Wealth Management LLC now owns 164,750 shares of the company’s stock worth $621,000 after purchasing an additional 163,500 shares in the last quarter. Signal Advisors Wealth LLC purchased a new position in Health Catalyst during the second quarter valued at $645,000. Acadian Asset Management LLC boosted its holdings in shares of Health Catalyst by 88.8% during the 1st quarter. Acadian Asset Management LLC now owns 930,229 shares of the company’s stock valued at $4,211,000 after buying an additional 437,536 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in shares of Health Catalyst in the 1st quarter worth about $46,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on HCAT shares. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, August 11th. Canaccord Genuity Group dropped their price target on Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 29th. Cantor Fitzgerald restated a “neutral” rating and issued a $4.00 price target on shares of Health Catalyst in a research note on Tuesday, October 7th. BTIG Research reiterated a “neutral” rating on shares of Health Catalyst in a research note on Friday, September 5th. Finally, Evercore ISI cut their target price on Health Catalyst from $4.00 to $3.00 and set an “in-line” rating on the stock in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.55.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT opened at $3.12 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83. The firm has a market cap of $219.55 million, a price-to-earnings ratio of -2.07 and a beta of 1.62. The business has a 50-day simple moving average of $3.06 and a two-hundred day simple moving average of $3.59. Health Catalyst, Inc. has a fifty-two week low of $2.52 and a fifty-two week high of $9.24.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.